Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
m
 
(16 intermediate revisions by 5 users not shown)
Line 1: Line 1:
 
{{TOCright}}
 
{{TOCright}}
 
:Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD  
 
:Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD  
:Secretary: Julie Lisiecki
+
:RSNA Staff Support: Julie Lisiecki
:Roster: [[Media:QIBA SPECT Roster.pdf| (Roster)]]
+
* [http://tinyurl.com/QIBA-SPECT-Roster Roster]
  
 
==Project Snapshot==
 
==Project Snapshot==
Line 11: Line 11:
 
*quantifying organs, like the liver, for dosimetry as potential use cases
 
*quantifying organs, like the liver, for dosimetry as potential use cases
  
'''Established Task Forces currently working toward a first Profile titled:
+
'''Established Task Forces''' currently working toward a first Profile titled: <font color=blue>''Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease''</font>   
 
<font color=blue>''Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease''</font>   
 
  
 
* Image Acquisition and Image Processing for DaTscan – ''Dr. Dewaraja''
 
* Image Acquisition and Image Processing for DaTscan – ''Dr. Dewaraja''
Line 20: Line 18:
 
* Clinical / Literature Review – ''Dr. Seibyl''
 
* Clinical / Literature Review – ''Dr. Seibyl''
  
==Meetings/Call Summaries==
+
==Recent Meetings/Call Summaries==
*[[SPECT Call Summaries]]
+
 
 +
*[[Media:02 16 2018 QIBA SPECT Call Summary-FINAL.pdf|February 16, 2018]]
 +
*[[Media:01 19 2018 QIBA SPECT Call Summary-FINAL.pdf|January 19, 2018]]
 +
*[[Media:10 20 2017 QIBA SPECT Call Summary-FINAL.pdf|October 20, 2017]]
 +
 
 +
'''''[[SPECT BC Call Summaries Archive]]'''''
  
 
==Literature Review (Profile 1.0)==
 
==Literature Review (Profile 1.0)==
Line 29: Line 32:
  
 
==Profile Development==
 
==Profile Development==
 +
 +
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.0 post-public comments.2017 08 29.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), August 28, 2017]]
 +
 +
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.0 post-public comments.clean copy.2017 06 26.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.1), June 26, 2017]]
 +
 +
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016]]
 +
 +
*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA Profile Checklist: SPECT Profile Conformance]]
  
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.05.10.docx | QIBA DRAFT Profile with tracked changes - {Dr. Miyaoka}]] ''May 10, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.05.10.docx | QIBA DRAFT Profile with tracked changes - {Dr. Miyaoka}]] ''May 10, 2016''
Line 37: Line 48:
  
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.04.05.docx | QIBA DRAFT Profile with tracked changes for recent additions and homework - {Dr. E. Frey}]] ''April 5, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.04.05.docx | QIBA DRAFT Profile with tracked changes for recent additions and homework - {Dr. E. Frey}]] ''April 5, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.21.some spring cleaning.docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Mozley}]] ''March 21, 2016''
 
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.16.some tracked changes-yuni.docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Dewaraja}]] ''March 16, 2016''
 
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.16.some tracked changes.docx | QIBA DRAFT Profile with tracked changes for recent additions - {Dr. Mozley}]] ''March 16, 2016''
 
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.03.16.docx | QIBA DRAFT Profile - {Dr. Miyaoka}]] ''March 15, 2016''
 
 
*[[Media:Draft Profile Section on Image Analysis 3.10.docx | QIBA DRAFT Profile Section 3.10 on Image Analysis - {Drs. Miyaoka and Seibyl}]] ''March 8, 2016''
 
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.02.17.docx | QIBA DRAFT Profile: Quantifying Dopamine Transporters with 123-Iodine Labeled Ioflupane in Neurodegenerative Disease - {comments from Mr. Cella}]] ''February 17, 2016''
 
  
 
*[[Profile drafts|Archived past versions of the Profile]]
 
*[[Profile drafts|Archived past versions of the Profile]]
 
  
 
==Reference Materials==
 
==Reference Materials==

Latest revision as of 16:51, 22 May 2019

Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD
RSNA Staff Support: Julie Lisiecki

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.

Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases

Established Task Forces currently working toward a first Profile titled: Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Recent Meetings/Call Summaries

SPECT BC Call Summaries Archive

Literature Review (Profile 1.0)

Profile Development

Reference Materials